ghkcu/epithalon GHK-Cu 50mg GHK-Cu Copper — 50mg |

Description

Because AOD 9604 does not bind the growth hormone receptor, it does not trigger the IGF-1 cascade

Conclusion Research on nanoparticles and their application in CNS diseases has seen substantial growth, with increasing focus on utilizing nanomedicine carriers to efficiently deliver drugs across the BBB for treating these conditions

This study also highlighted the improvement of cognitive function-derived PACOs, including enhanced learning and memory function, attenuated nerve damage repair, and inhibited neuronal apoptosis through the PI3K/Akt/GSK3 signaling pathway (Hao et al., 2023)

Tirzepatide Dual agonist : GLP-1 + GIP Central benchmark for dual incretin research Often discussed in relation to body-weight outcomes, glycaemic control and incretin signalling Single agonist : GLP-1 More selective and mechanistically narrower Common reference point for GLP-1 pathway research Triple agonist : GLP-1 + GIP + glucagon Broader receptor profile than Tirzepatide Often discussed in relation to weight loss, energy expenditure and next-generation multi-pathway metabolic modulation For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs